Gene Therapy Trial Approved For Rare Anemia

CHAPEL HILL, N.C. -- A gene therapy clinical trial for Fanconi anemia, a fatal inherited blood disease, is set to begin at the University of North Carolina at Chapel Hill.

Currently, the best survival hope for Fanconi patients is a bone marrow transplant from a donor with a perfect tissue match. However, for most patients, a suitable donor cannot be found in time.

"In people with Fanconi anemia, the bone marrow fails. It's a failure state like liver failure or heart failure," says Dr. Christopher E. Walsh, assistant professor of medicine at UNC-CH School of Medicine and clinical director of the university's Gene Therapy Center. "The bone marrow failure associated with this anemia leads to severe reductions in the numbers of circulating blood cells, including red cells, all types of white cells and platelets, which are crucial to clotting."

According to Walsh, the majority of individuals with Fanconi anemia are unaware they have the disease. "By and large, most patients come to medical attention because they have something wrong with their blood cell counts," he says. However, he notes that in some people with low cell counts, certain physical characteristics may raise medical suspicion of Fanconi. These can include short stature, finger deformities, and hyperpigmentation of the skin -- so-called "caf au lait" spots.

The phase I clinical trial will test the safety and feasibility of correcting the blood disorder by transferring a cloned corrective gene called FAA into a patient's very primitive bone marrow cells - "progenitor" stem cells from which all blood cells are formed. These progenitor cells, which have been removed from bone marrow for the gene transfer, are then re-infused into the patient. Compelling evidence from prior laboratory studies indicate that the corrective gene, when packaged with a retrovirus, can enter the cell nucleus and enable formation of the millions of healthy blood cells that are needed every day.

Fanconi anemi

Contact: Lynn Wooten
University of North Carolina at Chapel Hill

Page: 1 2

Related biology news :

1. 1st International Conference on Cell Therapy for Cardiovascular Disease
2. National Cancer Gene Therapy Foundation gives $4.0 million in research grants
3. Braunschweig Prize 2003 for Molecular Cancer Therapy
4. Alliance for Cancer Gene Therapy announces $1.5 million in national grants to young investigators
5. New research on safety of intracoronary delivery of adenovector reported in cover story of Molecular Therapy
6. Therapy hinders AIDS virus from evolving drug resistance, Hopkins researchers find
7. Invitation To Cover: American Society Of Gene Therapy Meeting
8. Gene Therapy For Pain
9. Role Of Protein Linked To Colon Cancer Identified, Offering Potential Target For Therapy
10. Shock Therapy Exceeds Expectations In Cleaning Up Contaminated Soils
11. Penn Researchers Develop Gene Therapy Technique That Reverses Muscle Membrane Weakness In Muscular Dystrophy Variant

Post Your Comments:

(Date:6/28/2020)... ... June 25, 2020 , ... ... biopharmaceutical R&D, today announced that it has entered into a multi-year contract ... (Multiclonics®), to support their translational and clinical research strategy to discover and ...
(Date:6/25/2020)... ... June 24, 2020 , ... ... software and software-driven clinical data services that accelerate drug development, is collaborating with ... an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the first ...
(Date:6/23/2020)... , ... June 23, 2020 , ... ... sustainable healthcare, and Renovagen Ltd, a UK supplier and manufacturer of innovative portable ... support testing operations in the fight against the COVID-19 pandemic in Zambia. , ...
Breaking Biology News(10 mins):
(Date:5/28/2020)... (PRWEB) , ... May 28, 2020 , ... The ... and security leaders as the 2020 winners of the Women in Biometrics Awards ... sponsors IDEMIA , Biometric Update and the SIA Women in ...
(Date:5/21/2020)... ... , ... Threats to intellectual property, political pressure to lower ... wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, a new ... commercially weaker, dealing with delays in new product launches and with fewer resources ...
(Date:5/21/2020)... ... ... Eaton Square is pleased to announce its growth on the East Coast of ... strategy and M&A advisory firm. , This is an important step for Eaton Square ... healthcare innovators with capital and investors. , Popper and Company, founded in 2003 by ...
(Date:5/15/2020)... (PRWEB) , ... May 14, ... ... supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC ... to enable streamlined and multi-format collection of hMSC-derived extracellular vesicles (EVs). RoosterCollect™-EV-CC ...
Breaking Biology Technology:
Cached News: